1. Home
  2. CYRX vs MYGN Comparison

CYRX vs MYGN Comparison

Compare CYRX & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CryoPort Inc.

CYRX

CryoPort Inc.

HOLD

Current Price

$8.05

Market Cap

421.6M

Sector

Health Care

ML Signal

HOLD

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

HOLD

Current Price

$5.14

Market Cap

481.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYRX
MYGN
Founded
1999
1991
Country
United States
United States
Employees
1100
2700
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
421.6M
481.6M
IPO Year
2008
1996

Fundamental Metrics

Financial Performance
Metric
CYRX
MYGN
Price
$8.05
$5.14
Analyst Decision
Strong Buy
Hold
Analyst Count
9
9
Target Price
$12.94
$8.06
AVG Volume (30 Days)
341.9K
1.3M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
156.22
N/A
EPS
1.40
N/A
Revenue
$176,177,000.00
$771,400,000.00
Revenue This Year
$9.71
$7.19
Revenue Next Year
$9.56
$5.64
P/E Ratio
$4.99
N/A
Revenue Growth
N/A
2.33
52 Week Low
$4.63
$3.76
52 Week High
$11.45
$11.44

Technical Indicators

Market Signals
Indicator
CYRX
MYGN
Relative Strength Index (RSI) 37.26 51.59
Support Level $6.57 $4.82
Resistance Level $8.45 $5.67
Average True Range (ATR) 0.51 0.39
MACD 0.04 0.13
Stochastic Oscillator 25.71 64.60

Price Performance

Historical Comparison
CYRX
MYGN

About CYRX CryoPort Inc.

CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

Share on Social Networks: